SlideShare a Scribd company logo
1 of 13
NEAVS
New England Anti-Vivisection Society
“Wait, remind me again who Kesha is?*”
*Or, other animal research issues to be
concerned about beyond cosmetics and
product testing
Thanks to EPA and ICCVAM for their leadership!
I. NEAVS
• Founded in 1895
• We exist to move society as quickly
as possible toward ending the use of
animals in research
Just kidding Kesha
But cosmetics are only a small part
of the problem
II. Overarching Threats: Government
Mandates and Funding
At a time when...
• Public opinion about animal research
indicates 44-50% of U.S. adults oppose the use
of animals in research. (Gallup) (Funk and Rainie, 2015)
• Between 50-89% of all preclinical research findings can not be reproduced.
(Freedman, Cockburn, and Simcoe, 2015)
• 95% failure rate of new drugs is largely a result of an approval process that
relies on animal experiments
• Yet, the government funds about 2/3 of all animal testing in the U.S at a cost
of $20bn
III. Current Threats
• The push for de-regulation
• USDA blackout
FASEB Reforming
Animal Research
Regulations:
Workshop
Recommendations
Points of contention with the FASEB et al. report
Reduction of burdensome bureaucracy is fine, but this cannot come at the
expense of animal welfare, lack of transparency, or weakened oversight.
• Moving to the lowest common denominator for species covered
• Moving from bi-annual to annual IACUC inspection
• Removing the requirement for annual USDA inspection
• Limiting IACUC oversight for “low risk, noninvasive, or minimally
invasive” research
• Limiting reporting to include only incidents that jeopardize the health
or wellbeing of animals
Open Comment Period
• Comments must be submitted
online by June 12th, 2018 by going
here
Transparency Issues
• APHIS redacting basic information,
including name of permitted
facilities and animal inventories
• FACT Act – Mandates reporting on
number of animals and types of
tests in tox research
IV. Our Strategies for Change
• Exposing abuse
• Changing policy
• Promoting human-relevant models
IV. Potential for a big win?
• At a minimum, I think we could all agree between 50-89% of tests—
those that are not replicable—should end. These tests are wasteful, cruel,
and serve no benefit to anyone other than the researchers earning salary
for their work and their affiliated institutions drawing overhead.
• This result might save over 50 million animals a year, worldwide.
Nathan Herschler
Executive Director
nherschler@neavs.org | 617-523-6020 | neavs.org
Contact

More Related Content

What's hot

A simulation model for African swine fever in domestic pigs and evaluation of...
A simulation model for African swine fever in domestic pigs and evaluation of...A simulation model for African swine fever in domestic pigs and evaluation of...
A simulation model for African swine fever in domestic pigs and evaluation of...ILRI
 
OncologyPipeline
OncologyPipelineOncologyPipeline
OncologyPipelineAndreas Abt
 
How can we assess the value of new antibiotics?
How can we assess the value of new antibiotics?How can we assess the value of new antibiotics?
How can we assess the value of new antibiotics?Office of Health Economics
 
Dr. Roger Saltman - The NIAA Effort: Learning from the June Roundtable
Dr. Roger Saltman - The NIAA Effort: Learning from the June RoundtableDr. Roger Saltman - The NIAA Effort: Learning from the June Roundtable
Dr. Roger Saltman - The NIAA Effort: Learning from the June RoundtableJohn Blue
 
ASCO 2014 Highlights: Breast Cancer, Prostate Cancer; AI diagnosing
ASCO 2014 Highlights: Breast Cancer, Prostate Cancer; AI diagnosingASCO 2014 Highlights: Breast Cancer, Prostate Cancer; AI diagnosing
ASCO 2014 Highlights: Breast Cancer, Prostate Cancer; AI diagnosingdianecleverley
 
UK AMR Diagnositics Collaborative
UK AMR Diagnositics CollaborativeUK AMR Diagnositics Collaborative
UK AMR Diagnositics CollaborativeWalt Whitman
 
Decentralized Clinical Trials: Collaboration to Accelerate Adoption
Decentralized Clinical Trials: Collaboration to Accelerate AdoptionDecentralized Clinical Trials: Collaboration to Accelerate Adoption
Decentralized Clinical Trials: Collaboration to Accelerate AdoptionCraig Lipset
 
Opportunity costs and local health service spending decisions: A qualitative ...
Opportunity costs and local health servicespending decisions: A qualitative ...Opportunity costs and local health servicespending decisions: A qualitative ...
Opportunity costs and local health service spending decisions: A qualitative ...Kerry Sheppard
 
Patient and doc engagement online west
Patient and doc engagement online westPatient and doc engagement online west
Patient and doc engagement online westH. Jack West
 
SMRH Working Group
SMRH Working GroupSMRH Working Group
SMRH Working GroupCORE Group
 
Earli19 presentation 13 aug19_charitonos_littlejohn
Earli19 presentation 13 aug19_charitonos_littlejohnEarli19 presentation 13 aug19_charitonos_littlejohn
Earli19 presentation 13 aug19_charitonos_littlejohnAllison Littlejohn
 
Are Existing HTA Requirements Inadequate for Establishing Value for Potential...
Are Existing HTA Requirements Inadequate for Establishing Value for Potential...Are Existing HTA Requirements Inadequate for Establishing Value for Potential...
Are Existing HTA Requirements Inadequate for Establishing Value for Potential...Office of Health Economics
 
Is willingness to pay higher for cancer prevention and treatment?
Is willingness to pay higher for cancer prevention and treatment?Is willingness to pay higher for cancer prevention and treatment?
Is willingness to pay higher for cancer prevention and treatment?Office of Health Economics
 
Pistoia Alliance US Conference 2015 - 1.1.4 Innovation in Pharma - Chris McKenna
Pistoia Alliance US Conference 2015 - 1.1.4 Innovation in Pharma - Chris McKennaPistoia Alliance US Conference 2015 - 1.1.4 Innovation in Pharma - Chris McKenna
Pistoia Alliance US Conference 2015 - 1.1.4 Innovation in Pharma - Chris McKennaPistoia Alliance
 
What Should Patient-Centered Care Mean in the Welfare States of Europe? The U...
What Should Patient-Centered Care Mean in the Welfare States of Europe? The U...What Should Patient-Centered Care Mean in the Welfare States of Europe? The U...
What Should Patient-Centered Care Mean in the Welfare States of Europe? The U...Office of Health Economics
 
Day 2: Danielle Rollmann, MIT FoCUS (Nov 19) Access to Innovation Conference ...
Day 2: Danielle Rollmann, MIT FoCUS (Nov 19) Access to Innovation Conference ...Day 2: Danielle Rollmann, MIT FoCUS (Nov 19) Access to Innovation Conference ...
Day 2: Danielle Rollmann, MIT FoCUS (Nov 19) Access to Innovation Conference ...Canadian Organization for Rare Disorders
 
PET Scans Ahmed
PET Scans AhmedPET Scans Ahmed
PET Scans Ahmedmswestrhss
 

What's hot (18)

A simulation model for African swine fever in domestic pigs and evaluation of...
A simulation model for African swine fever in domestic pigs and evaluation of...A simulation model for African swine fever in domestic pigs and evaluation of...
A simulation model for African swine fever in domestic pigs and evaluation of...
 
OncologyPipeline
OncologyPipelineOncologyPipeline
OncologyPipeline
 
How can we assess the value of new antibiotics?
How can we assess the value of new antibiotics?How can we assess the value of new antibiotics?
How can we assess the value of new antibiotics?
 
Dr. Roger Saltman - The NIAA Effort: Learning from the June Roundtable
Dr. Roger Saltman - The NIAA Effort: Learning from the June RoundtableDr. Roger Saltman - The NIAA Effort: Learning from the June Roundtable
Dr. Roger Saltman - The NIAA Effort: Learning from the June Roundtable
 
ASCO 2014 Highlights: Breast Cancer, Prostate Cancer; AI diagnosing
ASCO 2014 Highlights: Breast Cancer, Prostate Cancer; AI diagnosingASCO 2014 Highlights: Breast Cancer, Prostate Cancer; AI diagnosing
ASCO 2014 Highlights: Breast Cancer, Prostate Cancer; AI diagnosing
 
UK AMR Diagnositics Collaborative
UK AMR Diagnositics CollaborativeUK AMR Diagnositics Collaborative
UK AMR Diagnositics Collaborative
 
Decentralized Clinical Trials: Collaboration to Accelerate Adoption
Decentralized Clinical Trials: Collaboration to Accelerate AdoptionDecentralized Clinical Trials: Collaboration to Accelerate Adoption
Decentralized Clinical Trials: Collaboration to Accelerate Adoption
 
Opportunity costs and local health service spending decisions: A qualitative ...
Opportunity costs and local health servicespending decisions: A qualitative ...Opportunity costs and local health servicespending decisions: A qualitative ...
Opportunity costs and local health service spending decisions: A qualitative ...
 
Patient and doc engagement online west
Patient and doc engagement online westPatient and doc engagement online west
Patient and doc engagement online west
 
SMRH Working Group
SMRH Working GroupSMRH Working Group
SMRH Working Group
 
Earli19 presentation 13 aug19_charitonos_littlejohn
Earli19 presentation 13 aug19_charitonos_littlejohnEarli19 presentation 13 aug19_charitonos_littlejohn
Earli19 presentation 13 aug19_charitonos_littlejohn
 
Are Existing HTA Requirements Inadequate for Establishing Value for Potential...
Are Existing HTA Requirements Inadequate for Establishing Value for Potential...Are Existing HTA Requirements Inadequate for Establishing Value for Potential...
Are Existing HTA Requirements Inadequate for Establishing Value for Potential...
 
Is willingness to pay higher for cancer prevention and treatment?
Is willingness to pay higher for cancer prevention and treatment?Is willingness to pay higher for cancer prevention and treatment?
Is willingness to pay higher for cancer prevention and treatment?
 
Pistoia Alliance US Conference 2015 - 1.1.4 Innovation in Pharma - Chris McKenna
Pistoia Alliance US Conference 2015 - 1.1.4 Innovation in Pharma - Chris McKennaPistoia Alliance US Conference 2015 - 1.1.4 Innovation in Pharma - Chris McKenna
Pistoia Alliance US Conference 2015 - 1.1.4 Innovation in Pharma - Chris McKenna
 
What Should Patient-Centered Care Mean in the Welfare States of Europe? The U...
What Should Patient-Centered Care Mean in the Welfare States of Europe? The U...What Should Patient-Centered Care Mean in the Welfare States of Europe? The U...
What Should Patient-Centered Care Mean in the Welfare States of Europe? The U...
 
Company Overview
Company OverviewCompany Overview
Company Overview
 
Day 2: Danielle Rollmann, MIT FoCUS (Nov 19) Access to Innovation Conference ...
Day 2: Danielle Rollmann, MIT FoCUS (Nov 19) Access to Innovation Conference ...Day 2: Danielle Rollmann, MIT FoCUS (Nov 19) Access to Innovation Conference ...
Day 2: Danielle Rollmann, MIT FoCUS (Nov 19) Access to Innovation Conference ...
 
PET Scans Ahmed
PET Scans AhmedPET Scans Ahmed
PET Scans Ahmed
 

Similar to Beyond Cosmetics Testing: Other Animal Research Issues to be Concerned About

Globalization Of Clinical Trials 2010 Josep M. Badenas
Globalization Of Clinical Trials 2010   Josep M. BadenasGlobalization Of Clinical Trials 2010   Josep M. Badenas
Globalization Of Clinical Trials 2010 Josep M. Badenasjosepmariabadenas
 
Unveiling the complexity: understanding errors in animal experiments
Unveiling the complexity: understanding errors in animal experimentsUnveiling the complexity: understanding errors in animal experiments
Unveiling the complexity: understanding errors in animal experimentsSACHINNAYAK74
 
A Promulgation Of Incredulity In The Pharmaceutical Industry
A Promulgation Of Incredulity In  The Pharmaceutical IndustryA Promulgation Of Incredulity In  The Pharmaceutical Industry
A Promulgation Of Incredulity In The Pharmaceutical IndustryStuart Silverman
 
Dr. Lonnie King - One Health Antibiotic Stewardship - What MUST Be Done Next:...
Dr. Lonnie King - One Health Antibiotic Stewardship - What MUST Be Done Next:...Dr. Lonnie King - One Health Antibiotic Stewardship - What MUST Be Done Next:...
Dr. Lonnie King - One Health Antibiotic Stewardship - What MUST Be Done Next:...John Blue
 
Unveiling the complexity, errors in animal experiments
Unveiling the complexity, errors in animal experimentsUnveiling the complexity, errors in animal experiments
Unveiling the complexity, errors in animal experimentsSACHINNAYAK74
 
Research Animals
Research AnimalsResearch Animals
Research AnimalsHVCClibrary
 
Project Management_DM Presentation
Project Management_DM PresentationProject Management_DM Presentation
Project Management_DM PresentationDaniela Margiotta
 
Alice Avanian BSAS Presentation 9-15-15
Alice Avanian BSAS Presentation 9-15-15Alice Avanian BSAS Presentation 9-15-15
Alice Avanian BSAS Presentation 9-15-15Alice Avanian, CFA
 
Debate on " Whether clinical trials in developing countries are expolitative?"
Debate on " Whether clinical trials in developing countries are expolitative?"Debate on " Whether clinical trials in developing countries are expolitative?"
Debate on " Whether clinical trials in developing countries are expolitative?"Gopi sankar
 
Mr. Richard Coulter - Global Antibiotic Regulations
Mr. Richard Coulter - Global Antibiotic RegulationsMr. Richard Coulter - Global Antibiotic Regulations
Mr. Richard Coulter - Global Antibiotic RegulationsJohn Blue
 
Presentation: The Australian and International landscape - keynote forum
Presentation: The Australian and International landscape - keynote forumPresentation: The Australian and International landscape - keynote forum
Presentation: The Australian and International landscape - keynote forumTGA Australia
 
Realizing the potential for HIV self-testing - a summary of latest evidence
Realizing the potential for HIV self-testing - a summary of latest evidenceRealizing the potential for HIV self-testing - a summary of latest evidence
Realizing the potential for HIV self-testing - a summary of latest evidenceCheryl Johnson
 
AzCI presents: FDA Drug Development 101
AzCI presents: FDA Drug Development 101AzCI presents: FDA Drug Development 101
AzCI presents: FDA Drug Development 101AnitaBell
 
Why Clinical Quality Should Drive Healthcare Business Strategy
Why Clinical Quality Should Drive Healthcare Business StrategyWhy Clinical Quality Should Drive Healthcare Business Strategy
Why Clinical Quality Should Drive Healthcare Business StrategyHealth Catalyst
 
Rx15 tpp tues_330_1_gavin_2nader_3jeter
Rx15 tpp tues_330_1_gavin_2nader_3jeterRx15 tpp tues_330_1_gavin_2nader_3jeter
Rx15 tpp tues_330_1_gavin_2nader_3jeterOPUNITE
 
Types of Trials in Medicine, vaccine efficacy or effectiveness trials and rel...
Types of Trials in Medicine, vaccine efficacy or effectiveness trials and rel...Types of Trials in Medicine, vaccine efficacy or effectiveness trials and rel...
Types of Trials in Medicine, vaccine efficacy or effectiveness trials and rel...Bhoj Raj Singh
 

Similar to Beyond Cosmetics Testing: Other Animal Research Issues to be Concerned About (20)

Pharmacoepidemiology
PharmacoepidemiologyPharmacoepidemiology
Pharmacoepidemiology
 
Globalization Of Clinical Trials 2010 Josep M. Badenas
Globalization Of Clinical Trials 2010   Josep M. BadenasGlobalization Of Clinical Trials 2010   Josep M. Badenas
Globalization Of Clinical Trials 2010 Josep M. Badenas
 
Long Pet Pharmaceutical Industry
Long Pet Pharmaceutical IndustryLong Pet Pharmaceutical Industry
Long Pet Pharmaceutical Industry
 
Unveiling the complexity: understanding errors in animal experiments
Unveiling the complexity: understanding errors in animal experimentsUnveiling the complexity: understanding errors in animal experiments
Unveiling the complexity: understanding errors in animal experiments
 
A Promulgation Of Incredulity In The Pharmaceutical Industry
A Promulgation Of Incredulity In  The Pharmaceutical IndustryA Promulgation Of Incredulity In  The Pharmaceutical Industry
A Promulgation Of Incredulity In The Pharmaceutical Industry
 
RCT CH1.ppt
RCT CH1.pptRCT CH1.ppt
RCT CH1.ppt
 
Dr. Lonnie King - One Health Antibiotic Stewardship - What MUST Be Done Next:...
Dr. Lonnie King - One Health Antibiotic Stewardship - What MUST Be Done Next:...Dr. Lonnie King - One Health Antibiotic Stewardship - What MUST Be Done Next:...
Dr. Lonnie King - One Health Antibiotic Stewardship - What MUST Be Done Next:...
 
Unveiling the complexity, errors in animal experiments
Unveiling the complexity, errors in animal experimentsUnveiling the complexity, errors in animal experiments
Unveiling the complexity, errors in animal experiments
 
Research Animals
Research AnimalsResearch Animals
Research Animals
 
Project Management_DM Presentation
Project Management_DM PresentationProject Management_DM Presentation
Project Management_DM Presentation
 
Alice Avanian BSAS Presentation 9-15-15
Alice Avanian BSAS Presentation 9-15-15Alice Avanian BSAS Presentation 9-15-15
Alice Avanian BSAS Presentation 9-15-15
 
Debate on " Whether clinical trials in developing countries are expolitative?"
Debate on " Whether clinical trials in developing countries are expolitative?"Debate on " Whether clinical trials in developing countries are expolitative?"
Debate on " Whether clinical trials in developing countries are expolitative?"
 
Mr. Richard Coulter - Global Antibiotic Regulations
Mr. Richard Coulter - Global Antibiotic RegulationsMr. Richard Coulter - Global Antibiotic Regulations
Mr. Richard Coulter - Global Antibiotic Regulations
 
Presentation: The Australian and International landscape - keynote forum
Presentation: The Australian and International landscape - keynote forumPresentation: The Australian and International landscape - keynote forum
Presentation: The Australian and International landscape - keynote forum
 
Realizing the potential for HIV self-testing - a summary of latest evidence
Realizing the potential for HIV self-testing - a summary of latest evidenceRealizing the potential for HIV self-testing - a summary of latest evidence
Realizing the potential for HIV self-testing - a summary of latest evidence
 
AzCI presents: FDA Drug Development 101
AzCI presents: FDA Drug Development 101AzCI presents: FDA Drug Development 101
AzCI presents: FDA Drug Development 101
 
Why Clinical Quality Should Drive Healthcare Business Strategy
Why Clinical Quality Should Drive Healthcare Business StrategyWhy Clinical Quality Should Drive Healthcare Business Strategy
Why Clinical Quality Should Drive Healthcare Business Strategy
 
New Business Model for Antibiotics
New Business Model for AntibioticsNew Business Model for Antibiotics
New Business Model for Antibiotics
 
Rx15 tpp tues_330_1_gavin_2nader_3jeter
Rx15 tpp tues_330_1_gavin_2nader_3jeterRx15 tpp tues_330_1_gavin_2nader_3jeter
Rx15 tpp tues_330_1_gavin_2nader_3jeter
 
Types of Trials in Medicine, vaccine efficacy or effectiveness trials and rel...
Types of Trials in Medicine, vaccine efficacy or effectiveness trials and rel...Types of Trials in Medicine, vaccine efficacy or effectiveness trials and rel...
Types of Trials in Medicine, vaccine efficacy or effectiveness trials and rel...
 

Recently uploaded

What is Model Inheritance in Odoo 17 ERP
What is Model Inheritance in Odoo 17 ERPWhat is Model Inheritance in Odoo 17 ERP
What is Model Inheritance in Odoo 17 ERPCeline George
 
Meghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media ComponentMeghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media ComponentInMediaRes1
 
DATA STRUCTURE AND ALGORITHM for beginners
DATA STRUCTURE AND ALGORITHM for beginnersDATA STRUCTURE AND ALGORITHM for beginners
DATA STRUCTURE AND ALGORITHM for beginnersSabitha Banu
 
EPANDING THE CONTENT OF AN OUTLINE using notes.pptx
EPANDING THE CONTENT OF AN OUTLINE using notes.pptxEPANDING THE CONTENT OF AN OUTLINE using notes.pptx
EPANDING THE CONTENT OF AN OUTLINE using notes.pptxRaymartEstabillo3
 
Gas measurement O2,Co2,& ph) 04/2024.pptx
Gas measurement O2,Co2,& ph) 04/2024.pptxGas measurement O2,Co2,& ph) 04/2024.pptx
Gas measurement O2,Co2,& ph) 04/2024.pptxDr.Ibrahim Hassaan
 
ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...
ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...
ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...JhezDiaz1
 
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfEnzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfSumit Tiwari
 
How to Configure Email Server in Odoo 17
How to Configure Email Server in Odoo 17How to Configure Email Server in Odoo 17
How to Configure Email Server in Odoo 17Celine George
 
Hierarchy of management that covers different levels of management
Hierarchy of management that covers different levels of managementHierarchy of management that covers different levels of management
Hierarchy of management that covers different levels of managementmkooblal
 
Presiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha electionsPresiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha electionsanshu789521
 
CELL CYCLE Division Science 8 quarter IV.pptx
CELL CYCLE Division Science 8 quarter IV.pptxCELL CYCLE Division Science 8 quarter IV.pptx
CELL CYCLE Division Science 8 quarter IV.pptxJiesonDelaCerna
 
Final demo Grade 9 for demo Plan dessert.pptx
Final demo Grade 9 for demo Plan dessert.pptxFinal demo Grade 9 for demo Plan dessert.pptx
Final demo Grade 9 for demo Plan dessert.pptxAvyJaneVismanos
 
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...Marc Dusseiller Dusjagr
 
Employee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxEmployee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxNirmalaLoungPoorunde1
 
Blooming Together_ Growing a Community Garden Worksheet.docx
Blooming Together_ Growing a Community Garden Worksheet.docxBlooming Together_ Growing a Community Garden Worksheet.docx
Blooming Together_ Growing a Community Garden Worksheet.docxUnboundStockton
 
How to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptxHow to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptxmanuelaromero2013
 

Recently uploaded (20)

What is Model Inheritance in Odoo 17 ERP
What is Model Inheritance in Odoo 17 ERPWhat is Model Inheritance in Odoo 17 ERP
What is Model Inheritance in Odoo 17 ERP
 
Meghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media ComponentMeghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media Component
 
TataKelola dan KamSiber Kecerdasan Buatan v022.pdf
TataKelola dan KamSiber Kecerdasan Buatan v022.pdfTataKelola dan KamSiber Kecerdasan Buatan v022.pdf
TataKelola dan KamSiber Kecerdasan Buatan v022.pdf
 
DATA STRUCTURE AND ALGORITHM for beginners
DATA STRUCTURE AND ALGORITHM for beginnersDATA STRUCTURE AND ALGORITHM for beginners
DATA STRUCTURE AND ALGORITHM for beginners
 
9953330565 Low Rate Call Girls In Rohini Delhi NCR
9953330565 Low Rate Call Girls In Rohini  Delhi NCR9953330565 Low Rate Call Girls In Rohini  Delhi NCR
9953330565 Low Rate Call Girls In Rohini Delhi NCR
 
EPANDING THE CONTENT OF AN OUTLINE using notes.pptx
EPANDING THE CONTENT OF AN OUTLINE using notes.pptxEPANDING THE CONTENT OF AN OUTLINE using notes.pptx
EPANDING THE CONTENT OF AN OUTLINE using notes.pptx
 
Gas measurement O2,Co2,& ph) 04/2024.pptx
Gas measurement O2,Co2,& ph) 04/2024.pptxGas measurement O2,Co2,& ph) 04/2024.pptx
Gas measurement O2,Co2,& ph) 04/2024.pptx
 
ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...
ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...
ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...
 
ESSENTIAL of (CS/IT/IS) class 06 (database)
ESSENTIAL of (CS/IT/IS) class 06 (database)ESSENTIAL of (CS/IT/IS) class 06 (database)
ESSENTIAL of (CS/IT/IS) class 06 (database)
 
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfEnzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
 
How to Configure Email Server in Odoo 17
How to Configure Email Server in Odoo 17How to Configure Email Server in Odoo 17
How to Configure Email Server in Odoo 17
 
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
 
Hierarchy of management that covers different levels of management
Hierarchy of management that covers different levels of managementHierarchy of management that covers different levels of management
Hierarchy of management that covers different levels of management
 
Presiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha electionsPresiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha elections
 
CELL CYCLE Division Science 8 quarter IV.pptx
CELL CYCLE Division Science 8 quarter IV.pptxCELL CYCLE Division Science 8 quarter IV.pptx
CELL CYCLE Division Science 8 quarter IV.pptx
 
Final demo Grade 9 for demo Plan dessert.pptx
Final demo Grade 9 for demo Plan dessert.pptxFinal demo Grade 9 for demo Plan dessert.pptx
Final demo Grade 9 for demo Plan dessert.pptx
 
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
 
Employee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxEmployee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptx
 
Blooming Together_ Growing a Community Garden Worksheet.docx
Blooming Together_ Growing a Community Garden Worksheet.docxBlooming Together_ Growing a Community Garden Worksheet.docx
Blooming Together_ Growing a Community Garden Worksheet.docx
 
How to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptxHow to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptx
 

Beyond Cosmetics Testing: Other Animal Research Issues to be Concerned About

  • 1. NEAVS New England Anti-Vivisection Society “Wait, remind me again who Kesha is?*” *Or, other animal research issues to be concerned about beyond cosmetics and product testing
  • 2. Thanks to EPA and ICCVAM for their leadership!
  • 3. I. NEAVS • Founded in 1895 • We exist to move society as quickly as possible toward ending the use of animals in research
  • 4. Just kidding Kesha But cosmetics are only a small part of the problem
  • 5. II. Overarching Threats: Government Mandates and Funding At a time when... • Public opinion about animal research indicates 44-50% of U.S. adults oppose the use of animals in research. (Gallup) (Funk and Rainie, 2015) • Between 50-89% of all preclinical research findings can not be reproduced. (Freedman, Cockburn, and Simcoe, 2015) • 95% failure rate of new drugs is largely a result of an approval process that relies on animal experiments • Yet, the government funds about 2/3 of all animal testing in the U.S at a cost of $20bn
  • 6. III. Current Threats • The push for de-regulation • USDA blackout
  • 8. Points of contention with the FASEB et al. report Reduction of burdensome bureaucracy is fine, but this cannot come at the expense of animal welfare, lack of transparency, or weakened oversight. • Moving to the lowest common denominator for species covered • Moving from bi-annual to annual IACUC inspection • Removing the requirement for annual USDA inspection • Limiting IACUC oversight for “low risk, noninvasive, or minimally invasive” research • Limiting reporting to include only incidents that jeopardize the health or wellbeing of animals
  • 9. Open Comment Period • Comments must be submitted online by June 12th, 2018 by going here
  • 10. Transparency Issues • APHIS redacting basic information, including name of permitted facilities and animal inventories • FACT Act – Mandates reporting on number of animals and types of tests in tox research
  • 11. IV. Our Strategies for Change • Exposing abuse • Changing policy • Promoting human-relevant models
  • 12. IV. Potential for a big win? • At a minimum, I think we could all agree between 50-89% of tests— those that are not replicable—should end. These tests are wasteful, cruel, and serve no benefit to anyone other than the researchers earning salary for their work and their affiliated institutions drawing overhead. • This result might save over 50 million animals a year, worldwide.
  • 13. Nathan Herschler Executive Director nherschler@neavs.org | 617-523-6020 | neavs.org Contact

Editor's Notes

  1. First, I want to thank Ingrid and the AUWCL SALDF group for hosting this meeting, to everyone for attending, and to the ICVAAM representatives in the room who are making tremendous strides in replacing animal testing with non-animal methods.
  2. The New England Anti Vivisection Society (I’m going to refer to us as NEAVS from here on out), as you can all tell from our name, exists to move society as quickly as possible toward ending the use of animals in research. As you can see from this image from NEAVS’ first ever newsletter, published in 1915 for distribution to our membership, that NEAVS “opposes the contention of vivisectors, ‘implied or expressed,’… that it is no one’s business what happens to an animal, so long as the individual who is handling it can plead that to increase science is his aim.”
  3. 100-500k animals are used for cosmetics and personal care products annually, worldwide. This is a small portion of the more than 100 million animals used across research purposes. Ensuring that animals aren’t used for cosmetics testing is important. We should all support the Humane Cosmetics Act and shop cruelty free by using the CCIC “Leaping Bunny” program, but it is also true that there is very little animal testing in the United States for cosmetics. This is true internationally as well, except for companies that are looking to sell their products in China where testing in government-run labs is still a requirement.
  4. We understand that there’s tremendous regulatory burden associated with regulatory compliance. Unfortunately, we are very concerned that the report’s recommendations put far too much focus on recommendations reducing administration at the expense of animal welfare. Here are some of our key areas of concern:
  5. The conclusion of the FASEB report highlights that, quote, providing exceptional welfare is paramount when conducting animal research, and regulatory requirements are vital to ensuring that research is executed safely, ethically, and humanely. End quote. The push to amend regulations, policies, and even legislation as recommended in this report takes that commitment to welfare and oversight far too lightly. If relevant agencies and legislators decide to move on some of these recommendations, it’s likely that they will see strong and unified opposition from the animal protection community and the hundreds of millions of supporters across the United States we represent.
  6. In February 2017, USDA’s AHPIS electronic reading room went dark. In August 2017, the USDA announced that, with one exception, it had finished its review of the information it used to affirmatively post on its website, and had made final decisions about what materials it would continue to post in its Electronic Reading Room. The one exception was the animal inventories that accompany USDA inspection reports. As to those records, the agency informed the public that it “intend[ed] to make this information available in the future.” https://www.aphis.usda.gov/aphis/ourfocus/animalwelfare/sa_awa/awa‐ inspection‐and‐annual‐reports. 50. The USDA has redacted from the records it used to routinely post in its Electronic Reading Room information that would allow the public to identify by name, address, or license number of the majority of regulated entities. Prior to February 3, 2017, such information had previously not been redacted by the agency in its Electronic Reading Room. 51. The agency asserts that this same information that the agency had already publicly disclosed is now exempt from disclosure “to protect privacy interests.” 52. The USDA has not re-posted the animal inventories that are part of each inspection report, and it is now withholding from the public animal inventories that it had previously posted in its Electronic Reading Room prior to February 3, 2017. 53. Although the USDA has reposted all previously posted research facility annual reports for fiscal years 1999 through 2015, with respect to those annual reports, the USDA has not disclosed all of the “Column E explanations”—i.e. information required from regulated facilities explaining why they have not complied with minimum animal welfare standards and/or Case 1:18-cv-00887 Document 1 Filed 04/16/18 Page 18 of 29 19 why certain animals used in procedures involving pain and distress were not provided medication or other treatments to minimize their suffering—or the explanations for exceptions to compliance with the standards and regulations, see 9 C.F.R. § 2.36(b)(3), (7). Likewise, although the USDA has posted research facility annual reports for fiscal years 2016 and 2017, most—if not all—of these reports have been posted without the requisite explanation pages. 54. APHIS is also continuing to withhold from the public all of the enforcement records that it previously routinely disclosed to the public in its Electronic Reading Room, including official warning letters; voluntary settlement agreements between APHIS and regulated entities; and administrative complaints initiating formal administrative proceedings before the USDA’s OALJ. 55. Many of the enforcement records that the USDA has failed to re-post were already previously publicly available in the USDA’s Electronic Reading Room. 56. On January 18, 2018, Judge Cooper of this Court issued a memorandum opinion dismissing Plaintiffs’ earlier case on the ground that, because the USDA had made final decisions about what it would be re-posting in its Electronic Reading Room, Plaintiffs’ request for declaratory and injunctive relief with respect to their claim that such information must be affirmatively disclosed had become moot. However, with respect to such information, Judge Cooper specifically noted that Plaintiffs “may raise challenges to the redactions that now accompany these records.” Slip Op. at 7, n.3. 57. As to two categories of information that the agency had not reposted—i.e., certain enforcement records and the animal inventories that accompany all USDA inspection reports— Judge Cooper held that Plaintiffs had not adequately alleged that such records are subject to Case 1:18-cv-00887 Document 1 Filed 04/16/18 Page 19 of 29 20 FOIA’ s affirmative disclosure requirement. Hence, as to those records, he dismissed Plaintiffs’ claims without prejudice. Id. at 12. NOTE: In August, the USDA unveiled a new limited database to search for inspection reports and research facility annual reports. However, the documents posted have significant information redacted, including the name of some of the permitted facilities, and does not provide previously included information such as animal inventories. To date, the USDA also continues to withhold important enforcement action records such as administrative complaints and official warning letters. – ALDF http://aldf.org/press-room/press-releases/animal-legal-defense-fund-appeals-dismissal-lawsuit-usda-blackout-animal-welfare-records/
  7. In February 2017, USDA’s AHPIS electronic reading room went dark. In August 2017, the USDA announced that, with one exception, it had finished its review of the information it used to affirmatively post on its website, and had made final decisions about what materials it would continue to post in its Electronic Reading Room. The one exception was the animal inventories that accompany USDA inspection reports. As to those records, the agency informed the public that it “intend[ed] to make this information available in the future.” https://www.aphis.usda.gov/aphis/ourfocus/animalwelfare/sa_awa/awa‐ inspection‐and‐annual‐reports. 50. The USDA has redacted from the records it used to routinely post in its Electronic Reading Room information that would allow the public to identify by name, address, or license number of the majority of regulated entities. Prior to February 3, 2017, such information had previously not been redacted by the agency in its Electronic Reading Room. 51. The agency asserts that this same information that the agency had already publicly disclosed is now exempt from disclosure “to protect privacy interests.” 52. The USDA has not re-posted the animal inventories that are part of each inspection report, and it is now withholding from the public animal inventories that it had previously posted in its Electronic Reading Room prior to February 3, 2017. 53. Although the USDA has reposted all previously posted research facility annual reports for fiscal years 1999 through 2015, with respect to those annual reports, the USDA has not disclosed all of the “Column E explanations”—i.e. information required from regulated facilities explaining why they have not complied with minimum animal welfare standards and/or Case 1:18-cv-00887 Document 1 Filed 04/16/18 Page 18 of 29 19 why certain animals used in procedures involving pain and distress were not provided medication or other treatments to minimize their suffering—or the explanations for exceptions to compliance with the standards and regulations, see 9 C.F.R. § 2.36(b)(3), (7). Likewise, although the USDA has posted research facility annual reports for fiscal years 2016 and 2017, most—if not all—of these reports have been posted without the requisite explanation pages. 54. APHIS is also continuing to withhold from the public all of the enforcement records that it previously routinely disclosed to the public in its Electronic Reading Room, including official warning letters; voluntary settlement agreements between APHIS and regulated entities; and administrative complaints initiating formal administrative proceedings before the USDA’s OALJ. 55. Many of the enforcement records that the USDA has failed to re-post were already previously publicly available in the USDA’s Electronic Reading Room. 56. On January 18, 2018, Judge Cooper of this Court issued a memorandum opinion dismissing Plaintiffs’ earlier case on the ground that, because the USDA had made final decisions about what it would be re-posting in its Electronic Reading Room, Plaintiffs’ request for declaratory and injunctive relief with respect to their claim that such information must be affirmatively disclosed had become moot. However, with respect to such information, Judge Cooper specifically noted that Plaintiffs “may raise challenges to the redactions that now accompany these records.” Slip Op. at 7, n.3. 57. As to two categories of information that the agency had not reposted—i.e., certain enforcement records and the animal inventories that accompany all USDA inspection reports— Judge Cooper held that Plaintiffs had not adequately alleged that such records are subject to Case 1:18-cv-00887 Document 1 Filed 04/16/18 Page 19 of 29 20 FOIA’ s affirmative disclosure requirement. Hence, as to those records, he dismissed Plaintiffs’ claims without prejudice. Id. at 12. NOTE: In August, the USDA unveiled a new limited database to search for inspection reports and research facility annual reports. However, the documents posted have significant information redacted, including the name of some of the permitted facilities, and does not provide previously included information such as animal inventories. To date, the USDA also continues to withhold important enforcement action records such as administrative complaints and official warning letters. – ALDF http://aldf.org/press-room/press-releases/animal-legal-defense-fund-appeals-dismissal-lawsuit-usda-blackout-animal-welfare-records/
  8. How? Agency memoranda a la Chimpanzees requiring systematic review? Legislation? In the meantime, you can shop cruelty free using the Leaping Bunny program, support the Humane Cosmetics Act, make comments opposing deregulation that risks animal welfare, thank the EPA and ICCVAM for their leadership, support some of the state bills focusing on